Background
Meningioma is the most common tumour of the central nervous system of dogs. For this tumour, surgery remains the treatment of choice, either alone or in combination with radiotherapy. Unfortunately, chemotherapeutic strategies are practically absent in dogs and palliative therapies are the only option to surgery. Somatostatin receptor subtype 2 (SSTR2) is expressed in canine meningioma. Since the potent cell-proliferation inhibiting effect of somatostatin (SST), the aim of this study was to investigate in vitro the effects of octreotide, as SST analogue, in the viability of canine meningioma.
Methods
Four surgical canine meningiomas were used in this study to establish cell cultures. Expression of SSTR2 was verified with immunolabelling in PEFF and cell cultures. The effects of octreotide on cell viability were assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl-2H-tetrazolium bromide (MTT). After 24 hours they were exposed to different concentrations of octreotide (0.1 nM, 1 nM, 10 nM, 100nM) for 24h and 48h.
Results
All meningiomas consisted in grade I tumours. The cultured neoplastic cells expressed SSTR2 from 80% to 100%. Octreotide significantly increased cell death after 48h of continuous exposure, with 10 nM and 100 nM octreotide doses. The percentage of cell viability was 80.92 ±4.9 and 80.49 ±3.61, compared to the control, respectively, consistent with decreased cell viability of about 20% for both the doses.
Conclusions
Octreotide reduced the alive neoplastic cultured cells of low-grade canine meningioma in a dose-dependent pattern with continuous exposition for 48h. These results support an alternative systemic treatment of meningioma with octreotide in the dog,